Molecular markers such as the tandem duplication of FLT3, and mutations in DNMT3A and NPM1 [41–43] have also been reported as factors stratifying the cytogenetically intermediate-risk AML group. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.